It was a head-turning headline. Here's why the market was buzzing.

Moderna and Merck will present Phase 3 melanoma findings on Saturday for their personalized cancer treatment combined with ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the ...

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...

Following last month's super rally, a growing number of analysts are now calling for caution.

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...